Aramis Biotechnologies
Aramis Biotechnologies develops a plant-based biofabrication platform to produce novel vaccines, starting with a seasonal flu vaccine. This technology leverages the unique properties of plant cells to enhance public health responses to current and future pandemics.
- Biotechnology
Funding
Raised to date
$28.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional vaccine production methods often rely on mammalian or insect cell cultures, which can be slow, expensive, and difficult to scale rapidly in response to emerging pandemics. These methods may also require complex purification steps to remove unwanted cellular components, potentially affecting vaccine efficacy and safety.
Solution
Aramis Biotechnologies is developing a plant-based biofabrication platform for producing vaccines. By leveraging the unique capabilities of plant cells, the platform aims to offer a faster, more scalable, and cost-effective alternative to conventional vaccine manufacturing. The initial focus is on a seasonal influenza vaccine, which will serve as a proof-of-concept for expanding the platform to address other public health needs and future pandemics. The plant-based approach has the potential to simplify production, reduce manufacturing costs, and enhance the speed of vaccine development and deployment.
Target Audience
The primary target audience includes public health organizations, government agencies, and pharmaceutical companies seeking innovative and scalable vaccine production technologies.
Features
- Plant cell-based expression system for rapid protein production
- Scalable biofabrication process suitable for large-scale vaccine manufacturing
- Simplified purification process compared to traditional cell-culture methods
- Potential for reduced manufacturing costs and increased production speed
- Platform adaptable to various vaccine targets, including seasonal and pandemic threats